Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Apeiron

- PMLiVE

Sobi/Apellis’ pegcetacoplan shows sustained efficacy in phase 3 kidney disease study

C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe

- PMLiVE

AXON NAMES NEW PRESIDENT AND MANAGING PARTNER, TINA HAHN, AS RALPH SUTTON CHANGES LANE

April 30, 2025—Tina Hahn, who joined AXON in 2012 as Vice President, will now take on the role of AXON’s President and Managing Partner.

AXON

- PMLiVE

Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

Approximately 7,700 people in England are living with the genetic bleeding disorder

- PMLiVE

Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A

The factor VIII replacement therapy has been authorised to treat and prevent bleeding in children and adults

- PMLiVE

Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study

There are currently no treatments that target the underlying cause of C3G or IC-MPGN

- PMLiVE

Sanofi/Sobi’s haemophilia A therapy shows ‘highly effective’ bleed protection in children

The rare bleeding disorder affects approximately one in every 5,000 male births annually

- PMLiVE

Sobi receives EC marketing authorisation for Altuvoct in haemophilia A

The rare bleeding disorder affects approximately one in every 5,000 male births annually

- PMLiVE

Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A

The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies

- PMLiVE

Sobi’s Aspaveli receives expanded EC approval for rare blood disorder PNH

The C3 therapy can now be used as a first-line treatment for paroxysmal nocturnal haemoglobinuria

- PMLiVE

Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A

The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting

- PMLiVE

Sobi shares positive phase 3 results for Doptelet in paediatric patients with rare blood disorder ITP

Immune thrombocytopenia is estimated to affect up to 100 people per million

- PMLiVE

Sobi receives NICE recommendation for Zynlonta in two non-Hodgkin lymphomas

Over 10,000 people are diagnosed with a type of non-Hodgkin lymphoma every year in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links